Q-omics provides the consensus-scored CACNB4 profile across patient tissues and cancer cell-line models. CACNB4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CACNB4 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CACNB4 RNA expression shows 18,711 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where CACNB4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACNB4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACNB4 survival associations across molecular data types. CACNB4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACNB4 RNA expression–survival associations across cancer types. High CACNB4 expression shows unfavorable associations in UVM, ACC and THCA, but favorable associations in HNSC, PAAD and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CACNB4 RNA expression.
This table summarizes CACNB4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CACNB4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACNB4 shows lower tumor expression in HNSC, LUAD, LUSC, KIRC, BLCA and THCA. The HNSC box plot shows higher CACNB4 RNA expression in normal versus tumor tissue (log2 FC = −0.812, t-test p < 0.001).
This table shows molecular features associated with CACNB4 in patient tissues and cancer cell lines. In patient samples, CACNB4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CACNB4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
